# Nautilus Biotechnology Inc. (NAUT) fundamentals

Data as of 2026-11-10. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.32, market value $296 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Nautilus Biotechnology Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -18.7%** (5-yr avg -19.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -37.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 16.1%**. Earnings per share rose 16.1%.

## Financial health
- **Current ratio: 13.33** (quick 13.33). Current assets cover the next year's liabilities 13.33 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Nautilus Biotechnology Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover Nautilus Biotechnology Inc.; the consensus is strong_buy, with an average price target of $4.00 (+72% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 57.6%** (YTD 22.1%, 3-mo 175.1%). The shares are up 57.6% over twelve months including dividends.
- **From 52-week high: -46.2%** (175.9% above the low). Trading 46% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.60** (volatility 118%). Beta of 1.60 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NAUT · Page: https://foliofundamentals.com/stocks/naut

Not investment advice.